GLP‐1 receptor agonists are now routinely used to treat obesity and type 2 diabetes [12], but the impact of intestinal pH on enteroendocrine EEC activity, and specifically GLP‐1 secretion, remains unknown. The gene discussed is GLP1R; the disease is obesity disorder.